Senzime Launches New Sustainable TetraSens EMG Sensor
UPPSALA, Sweden, June 1, 2026 Senzime AB announced the commercial launch of its next-generation TetraSens® electromyography (EMG) sensor, designed...
Alzheimer’s Disease ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
UPPSALA, Sweden, June 1, 2026 Senzime AB announced the commercial launch of its next-generation TetraSens® electromyography (EMG) sensor, designed...
UPPSALA, Sweden, May 27, 2026 Senzime AB announced that the U.S. Food and Drug Administration has granted an additional...
